Every 10-Q that Claritev Corporation (CTEV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CTEV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTEV filings page.
Claritev Corporation, a healthcare technology and data company, reported Q2 2026 revenue of $257,478 thousand, up 6.6% year over year, driven by 13.7% growth in Claims Intelligence Solutions. Network Solutions and Payment & Revenue Integrity declined modestly. Operating income rose to $23,409 thousand, but interest expense of $100,253 thousand led to a net loss of $59,226 thousand (loss per share $3.49). EBITDA was $134,113 thousand and Adjusted EBITDA $155,799 thousand; Adjusted EPS was $1.41.
As of June 30, 2026, Claritev held $27.7 million in cash and restricted cash and carried gross long-term debt of $4,637,003 thousand, resulting in a total shareholders’ deficit of $287,839 thousand. The company had $70.0 million drawn and $273.6 million available under its $350.0 million revolving credit facility. Operating cash flow for the first half was $46,892 thousand, partly funding $84,847 thousand of capital expenditures tied to its Vision 2030 transformation program.
Claritev disclosed ongoing multidistrict antitrust litigation and a civil Department of Justice inquiry, while noting the DOJ closed a related antitrust grand jury proceeding and confirmed it was not pursuing a criminal investigation. One client represented 35.0% of Q2 revenue. Management reported a continuing material weakness in IT general controls, leaving disclosure controls not effective while remediation efforts continue.
Claritev Corporation reported Q3 2025 results with revenue of $245,959 thousand, up from $230,495 thousand a year ago. Operating income was $10,067 thousand versus an operating loss last year, while net loss narrowed to $69,753 thousand from $391,450 thousand. Net loss per share was $4.23, adjusted for the 1-for-40 reverse split.
For the first nine months, revenue reached $718,859 thousand versus $698,479 thousand, with operating income of $36,387 thousand and a net loss of $203,712 thousand. Year-to-date operating cash flow was $51,038 thousand. Cash and cash equivalents were $39,152 thousand, plus $11,493 thousand of restricted cash, as of September 30, 2025. Long-term debt (net) was $4,546,671 thousand and shareholders’ deficit was $101,835 thousand. The company completed a January 30, 2025 refinancing, established a $350,000 thousand revolving credit facility (with $70,000 thousand outstanding at quarter end), and recorded interest expense of $101,232 thousand in Q3.